 | • レポートコード：MRC23Q37869 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、85ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のメニエール病治療薬市場について調査・分析し、世界のメニエール病治療薬市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（搭乗式酔い薬、吐き気止め薬、利尿薬、その他）、用途別セグメント分析（病院、クリニック）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Roche、Novartis、Pfizer、Auris Medical、Jubilant Cadista、Otonomy、Sound Pharmaceuticals、WellSpring Pharmaceuticalなどが含まれています。 世界のメニエール病治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、メニエール病治療薬市場規模を推定する際に考慮しました。本レポートは、メニエール病治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、メニエール病治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・メニエール病治療薬市場の概要 - 製品の定義 - メニエール病治療薬のタイプ別セグメント - 世界のメニエール病治療薬市場規模：タイプ別分析（搭乗式酔い薬、吐き気止め薬、利尿薬、その他） - メニエール病治療薬の用途別セグメント - 世界のメニエール病治療薬市場規模：用途別分析（病院、クリニック） - 世界のメニエール病治療薬市場規模予測（2018年-2029年） - メニエール病治療薬の平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - メニエール病治療薬市場の競争状況およびトレンド ・メニエール病治療薬の地域別市場規模 - 北米のメニエール病治療薬市場規模（2018年-2029年） - アメリカのメニエール病治療薬市場規模（2018年-2029年） - ヨーロッパのメニエール病治療薬市場規模（2018年-2029年） - アジア太平洋のメニエール病治療薬市場規模（2018年-2029年） - 中国のメニエール病治療薬市場規模（2018年-2029年） - 日本のメニエール病治療薬市場規模（2018年-2029年） - 韓国のメニエール病治療薬市場規模（2018年-2029年） - インドのメニエール病治療薬市場規模（2018年-2029年） - オーストラリアのメニエール病治療薬市場規模（2018年-2029年） - 中南米のメニエール病治療薬市場規模（2018年-2029年） - 中東・アフリカのメニエール病治療薬市場規模（2018年-2029年） ・タイプ別セグメント：搭乗式酔い薬、吐き気止め薬、利尿薬、その他 - 世界のメニエール病治療薬のタイプ別販売量（2018年-2023年） - 世界のメニエール病治療薬のタイプ別売上（2018年-2023年） - 世界のメニエール病治療薬のタイプ別価格 ・用途別セグメント：病院、クリニック - 世界のメニエール病治療薬の用途別販売量（2018年-2023年） - 世界のメニエール病治療薬の用途別売上（2018年-2023年） - 世界のメニエール病治療薬の用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Roche、Novartis、Pfizer、Auris Medical、Jubilant Cadista、Otonomy、Sound Pharmaceuticals、WellSpring Pharmaceutical ・産業チェーンと販売チャネルの分析 - メニエール病治療薬産業チェーン分析 - メニエール病治療薬の主要原材料 - メニエール病治療薬の販売チャネル - メニエール病治療薬のディストリビューター - メニエール病治療薬の主要顧客 ・メニエール病治療薬市場ダイナミクス - メニエール病治療薬の業界動向 - メニエール病治療薬市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Highlights
The global Meniere’s Disease Medications for Vertigo market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Meniere’s Disease Medications for Vertigo is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Meniere’s Disease Medications for Vertigo is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Meniere’s Disease Medications for Vertigo include Roche, Novartis, Pfizer, Auris Medical, Jubilant Cadista, Otonomy, Sound Pharmaceuticals and WellSpring Pharmaceutical, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Meniere’s Disease Medications for Vertigo, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meniere’s Disease Medications for Vertigo.
The Meniere’s Disease Medications for Vertigo market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Meniere’s Disease Medications for Vertigo market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Meniere’s Disease Medications for Vertigo manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Roche
Novartis
Pfizer
Auris Medical
Jubilant Cadista
Otonomy
Sound Pharmaceuticals
WellSpring Pharmaceutical
Segment by Type
Motion Sickness Drugs
Drugs for Nausea
Diuretics
Others
Segment by Application
Hospitals
Clinics
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Meniere’s Disease Medications for Vertigo manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Meniere’s Disease Medications for Vertigo in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Meniere’s Disease Medications for Vertigo Market Overview
1.1 Product Overview and Scope of Meniere’s Disease Medications for Vertigo
1.2 Meniere’s Disease Medications for Vertigo Segment by Type
1.2.1 Global Meniere’s Disease Medications for Vertigo Market Value Comparison by Type (2023-2029)
1.2.2 Motion Sickness Drugs
1.2.3 Drugs for Nausea
1.2.4 Diuretics
1.2.5 Others
1.3 Meniere’s Disease Medications for Vertigo Segment by Application
1.3.1 Global Meniere’s Disease Medications for Vertigo Market Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Clinics
1.4 Global Meniere’s Disease Medications for Vertigo Market Size Estimates and Forecasts
1.4.1 Global Meniere’s Disease Medications for Vertigo Revenue 2018-2029
1.4.2 Global Meniere’s Disease Medications for Vertigo Sales 2018-2029
1.4.3 Global Meniere’s Disease Medications for Vertigo Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Meniere’s Disease Medications for Vertigo Market Competition by Manufacturers
2.1 Global Meniere’s Disease Medications for Vertigo Sales Market Share by Manufacturers (2018-2023)
2.2 Global Meniere’s Disease Medications for Vertigo Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Meniere’s Disease Medications for Vertigo Average Price by Manufacturers (2018-2023)
2.4 Global Meniere’s Disease Medications for Vertigo Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Meniere’s Disease Medications for Vertigo, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Meniere’s Disease Medications for Vertigo, Product Type & Application
2.7 Meniere’s Disease Medications for Vertigo Market Competitive Situation and Trends
2.7.1 Meniere’s Disease Medications for Vertigo Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Meniere’s Disease Medications for Vertigo Players Market Share by Revenue
2.7.3 Global Meniere’s Disease Medications for Vertigo Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Meniere’s Disease Medications for Vertigo Retrospective Market Scenario by Region
3.1 Global Meniere’s Disease Medications for Vertigo Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Meniere’s Disease Medications for Vertigo Global Meniere’s Disease Medications for Vertigo Sales by Region: 2018-2029
3.2.1 Global Meniere’s Disease Medications for Vertigo Sales by Region: 2018-2023
3.2.2 Global Meniere’s Disease Medications for Vertigo Sales by Region: 2024-2029
3.3 Global Meniere’s Disease Medications for Vertigo Global Meniere’s Disease Medications for Vertigo Revenue by Region: 2018-2029
3.3.1 Global Meniere’s Disease Medications for Vertigo Revenue by Region: 2018-2023
3.3.2 Global Meniere’s Disease Medications for Vertigo Revenue by Region: 2024-2029
3.4 North America Meniere’s Disease Medications for Vertigo Market Facts & Figures by Country
3.4.1 North America Meniere’s Disease Medications for Vertigo Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Meniere’s Disease Medications for Vertigo Sales by Country (2018-2029)
3.4.3 North America Meniere’s Disease Medications for Vertigo Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Meniere’s Disease Medications for Vertigo Market Facts & Figures by Country
3.5.1 Europe Meniere’s Disease Medications for Vertigo Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Meniere’s Disease Medications for Vertigo Sales by Country (2018-2029)
3.5.3 Europe Meniere’s Disease Medications for Vertigo Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Meniere’s Disease Medications for Vertigo Market Facts & Figures by Country
3.6.1 Asia Pacific Meniere’s Disease Medications for Vertigo Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Meniere’s Disease Medications for Vertigo Sales by Country (2018-2029)
3.6.3 Asia Pacific Meniere’s Disease Medications for Vertigo Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Meniere’s Disease Medications for Vertigo Market Facts & Figures by Country
3.7.1 Latin America Meniere’s Disease Medications for Vertigo Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Meniere’s Disease Medications for Vertigo Sales by Country (2018-2029)
3.7.3 Latin America Meniere’s Disease Medications for Vertigo Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Meniere’s Disease Medications for Vertigo Market Facts & Figures by Country
3.8.1 Middle East and Africa Meniere’s Disease Medications for Vertigo Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Meniere’s Disease Medications for Vertigo Sales by Country (2018-2029)
3.8.3 Middle East and Africa Meniere’s Disease Medications for Vertigo Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Meniere’s Disease Medications for Vertigo Sales by Type (2018-2029)
4.1.1 Global Meniere’s Disease Medications for Vertigo Sales by Type (2018-2023)
4.1.2 Global Meniere’s Disease Medications for Vertigo Sales by Type (2024-2029)
4.1.3 Global Meniere’s Disease Medications for Vertigo Sales Market Share by Type (2018-2029)
4.2 Global Meniere’s Disease Medications for Vertigo Revenue by Type (2018-2029)
4.2.1 Global Meniere’s Disease Medications for Vertigo Revenue by Type (2018-2023)
4.2.2 Global Meniere’s Disease Medications for Vertigo Revenue by Type (2024-2029)
4.2.3 Global Meniere’s Disease Medications for Vertigo Revenue Market Share by Type (2018-2029)
4.3 Global Meniere’s Disease Medications for Vertigo Price by Type (2018-2029)
5 Segment by Application
5.1 Global Meniere’s Disease Medications for Vertigo Sales by Application (2018-2029)
5.1.1 Global Meniere’s Disease Medications for Vertigo Sales by Application (2018-2023)
5.1.2 Global Meniere’s Disease Medications for Vertigo Sales by Application (2024-2029)
5.1.3 Global Meniere’s Disease Medications for Vertigo Sales Market Share by Application (2018-2029)
5.2 Global Meniere’s Disease Medications for Vertigo Revenue by Application (2018-2029)
5.2.1 Global Meniere’s Disease Medications for Vertigo Revenue by Application (2018-2023)
5.2.2 Global Meniere’s Disease Medications for Vertigo Revenue by Application (2024-2029)
5.2.3 Global Meniere’s Disease Medications for Vertigo Revenue Market Share by Application (2018-2029)
5.3 Global Meniere’s Disease Medications for Vertigo Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Roche Meniere’s Disease Medications for Vertigo Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novartis Meniere’s Disease Medications for Vertigo Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer Meniere’s Disease Medications for Vertigo Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Auris Medical
6.4.1 Auris Medical Corporation Information
6.4.2 Auris Medical Description and Business Overview
6.4.3 Auris Medical Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Auris Medical Meniere’s Disease Medications for Vertigo Product Portfolio
6.4.5 Auris Medical Recent Developments/Updates
6.5 Jubilant Cadista
6.5.1 Jubilant Cadista Corporation Information
6.5.2 Jubilant Cadista Description and Business Overview
6.5.3 Jubilant Cadista Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Jubilant Cadista Meniere’s Disease Medications for Vertigo Product Portfolio
6.5.5 Jubilant Cadista Recent Developments/Updates
6.6 Otonomy
6.6.1 Otonomy Corporation Information
6.6.2 Otonomy Description and Business Overview
6.6.3 Otonomy Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Otonomy Meniere’s Disease Medications for Vertigo Product Portfolio
6.6.5 Otonomy Recent Developments/Updates
6.7 Sound Pharmaceuticals
6.6.1 Sound Pharmaceuticals Corporation Information
6.6.2 Sound Pharmaceuticals Description and Business Overview
6.6.3 Sound Pharmaceuticals Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Sound Pharmaceuticals Meniere’s Disease Medications for Vertigo Product Portfolio
6.7.5 Sound Pharmaceuticals Recent Developments/Updates
6.8 WellSpring Pharmaceutical
6.8.1 WellSpring Pharmaceutical Corporation Information
6.8.2 WellSpring Pharmaceutical Description and Business Overview
6.8.3 WellSpring Pharmaceutical Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.8.4 WellSpring Pharmaceutical Meniere’s Disease Medications for Vertigo Product Portfolio
6.8.5 WellSpring Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Meniere’s Disease Medications for Vertigo Industry Chain Analysis
7.2 Meniere’s Disease Medications for Vertigo Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Meniere’s Disease Medications for Vertigo Production Mode & Process
7.4 Meniere’s Disease Medications for Vertigo Sales and Marketing
7.4.1 Meniere’s Disease Medications for Vertigo Sales Channels
7.4.2 Meniere’s Disease Medications for Vertigo Distributors
7.5 Meniere’s Disease Medications for Vertigo Customers
8 Meniere’s Disease Medications for Vertigo Market Dynamics
8.1 Meniere’s Disease Medications for Vertigo Industry Trends
8.2 Meniere’s Disease Medications for Vertigo Market Drivers
8.3 Meniere’s Disease Medications for Vertigo Market Challenges
8.4 Meniere’s Disease Medications for Vertigo Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer